An observational study in Viral Control, Quality of Life and Cabotegravir, sponsored by National Taiwan University Clinical Trial Center. Not yet recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-08-20.
Sponsored by National Taiwan University Clinical Trial Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Acquired Immunodeficiency Syndrome with a site in Taiwan — 3 open to participants now, 4 under way, none of them phase 3. Acquired Immunodeficiency Syndrome · Taiwan.
Among the 22 studies in Acquired Immunodeficiency Syndrome with a site in Taiwan, this one is the only one that started in 2025, is one of 10 observational ones, and was the 21st registered.
3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →3 of the 22 studies in Acquired Immunodeficiency Syndrome with a site in Taiwan are open now. Recruiting first, the newest first:
National Taiwan University · Sites in Taiwan
Ages 30+
National Taiwan University Clinical Trial Center · Sites in Taiwan
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is below the median of 289 across 504 observational studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 425 across the 12 interventional studies, 300 across the 9 observational. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 22 have an industry lead sponsor. The 9 most frequent:
National Taiwan University Clinical Trial Center is the lead sponsor of 10 studies on the registry; 8 are open to participants now.
National Taiwan University Clinical Trial Center has 2 studies filed under Acquired Immunodeficiency Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Acquired Immunodeficiency Syndrome with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07131826National Taiwan University Clinical Trial CenterThe Quality of Life and Viral Control Effect of AIDS Patients After Long-acting Injection of Cabotegravir and Rilpivirine | 2026-12-31 |
| NCT06497504GlaxoSmithKlineStudy of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) | 2027-04-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Acquired Immunodeficiency Syndrome with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
"AIDS" was once regarded as the Black Death of the 20th century. However, with the advent of cocktail therapy, the survival rate of infected people has been greatly improved and the average life expectancy has been increased. Today, AIDS is considered a chronic disease, just like hypertension and diabetes. As long as you have regular checkups and take medication on time every day, you can complete the treatment, just like a normal person. However, there is still a risk of missing medication when taking it every day, and long-term missed medications can easily lead to drug resistance and increase the risk of treatment failure. After the HIV-infected person has stabilized the viral load, their mobility, self-care and daily activities are no different from those of normal people. However, they experience side effects such as fatigue, lack of energy, difficulty sleeping, depression, changes in appearance, tension and anxiety, dizziness, headache, vomiting, etc., which affect their quality of life. The long-acting AIDS injection is a long-acting dosage form for intramuscular injection. It has been included in the national health insurance reimbursement standards. Treatment with long-acting injections can reduce the risk of infected people forgetting to take medicine, and there is no need to worry about the exposure of the disease when storing the medicine. Through this study, we hope to collect the results of long-acting injections for stable HIV treatment cases (health status, daily activities, injection site, satisfaction), and confirm that long-acting injections can significantly improve the quality of daily life of HIV-infected people.
Males or females aged 18 years or older who have completed long-acting injectable treatment for HIV infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
18 years and above Clinical diagnosis of infection completed long-acting injectable treatment Accept the questionnaire
Exclusion Criteria:
Not clinical diagnosis of infection Do not accept questionnaires
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AIDS patients after long-acting injection of cabotegravir and rilpivirine
Other: Observational study, non-interventional
Observational study, non-interventional
To whether long-acting injections can significantly improve the quality of daily life of people infected with HIV using a questionnaire
Time frame: From the date of approval by the CTC to December 31, 2026.
Plan to share: Yes — Does the long-acting injection improve the quality of daily life of HIV-infected people?
Supporting information: Study protocol
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Dec 2026, 16 months later.
Of 165 non-industry observational studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 83. This study's planned 16 months is below that.
Counting every sponsor, half of 177 studies reached it within 44 months; a quarter within 19 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acquired Immunodeficiency Syndrome →
National Taiwan University Clinical Trial Center